Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
* Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents inJapan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious d...
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
* Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 inAustralia GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines fo...
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
* Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series * FDA has determined that first vaccine lot has met all release specifications and is acceptable for use underEmergency Use Authorization * Novavax expects ...
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /P...
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
* Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md. ,July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-gene...
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
* Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 inEurope GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf...
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
* Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 inEurope * Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechn...
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
* In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-...
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
* Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee * If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine availa...
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
* Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenic * Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 * Immune response confirmed in st...
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
* Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older inJapan * Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination GAITHERSBURG, Md., April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
* New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress * Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 /PRNewswire/ -- Novavax...
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
GAITHERSBURG, Md., and PUNE, India, April 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine ...
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
* If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years inEurope GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializi...
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India
* First authorization of Novavax' COVID-19 vaccine in adolescent population received * Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorizedfor adolescents ≥12 to <18 inIndia * Authorization highligh...
Novavax Announces Launch of Global Vaccine Education Programs
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines - Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company de...
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, In...
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Singapore GAITHERSBURG, Md., Feb. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, toda...
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in adolescents than in...
New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...
